^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | APG-1387 (IAP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.
Published date:
05/13/2020
Excerpt:
1 with ER+, HER2‒ breast cancer receiving APG-1387 30 mg after failing 5 lines of therapy (PD-1 treatment-naïve, microsatellite stable) achieved confirmed PR (-79.2%) for 6 cycles but discontinued due to pneumonitis…
DOI:
10.1200/JCO.2020.38.15_suppl.3508
Trial ID:
